CA2508722A1 - Controlled-release of an active substance into a high fat environment - Google Patents

Controlled-release of an active substance into a high fat environment Download PDF

Info

Publication number
CA2508722A1
CA2508722A1 CA002508722A CA2508722A CA2508722A1 CA 2508722 A1 CA2508722 A1 CA 2508722A1 CA 002508722 A CA002508722 A CA 002508722A CA 2508722 A CA2508722 A CA 2508722A CA 2508722 A1 CA2508722 A1 CA 2508722A1
Authority
CA
Canada
Prior art keywords
use environment
composition
release
fold
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508722A
Other languages
English (en)
French (fr)
Inventor
Mark Brian Chidlaw
Dwayne Thomas Friesen
Scott Max Herbig
James Alan Schriver Nightingale
Cynthia Ann Oksanen
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2508722A1 publication Critical patent/CA2508722A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002508722A 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment Abandoned CA2508722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11
US60/432,860 2002-12-11
PCT/IB2003/005629 WO2004052343A1 (en) 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment

Publications (1)

Publication Number Publication Date
CA2508722A1 true CA2508722A1 (en) 2004-06-24

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508722A Abandoned CA2508722A1 (en) 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment

Country Status (18)

Country Link
US (1) US20040121015A1 (https=)
EP (1) EP1572163A1 (https=)
JP (1) JP2006510655A (https=)
KR (1) KR20050088311A (https=)
CN (1) CN1726012A (https=)
AR (1) AR042340A1 (https=)
AU (1) AU2003283688A1 (https=)
BR (1) BR0317275A (https=)
CA (1) CA2508722A1 (https=)
CO (1) CO5570656A2 (https=)
MX (1) MXPA05005812A (https=)
NO (1) NO20053068L (https=)
NZ (1) NZ539915A (https=)
PL (1) PL377479A1 (https=)
RU (1) RU2308263C2 (https=)
TW (1) TWI257302B (https=)
WO (1) WO2004052343A1 (https=)
ZA (1) ZA200503812B (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US20080138428A1 (en) * 2005-01-28 2008-06-12 Pfizer Inc. Fast-Disintegrating Microporous Binders
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
EP2013829A4 (en) 2006-05-02 2010-07-07 Proteus Biomedical Inc PERSONALIZED THERAPEUTIC REGIMES FOR A PATIENT
WO2008066617A2 (en) 2006-10-17 2008-06-05 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
WO2008052136A2 (en) * 2006-10-25 2008-05-02 Proteus Biomedical, Inc. Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
EP3785599B1 (en) 2007-02-01 2022-08-03 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker systems
US8956288B2 (en) * 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
EP2124725A1 (en) 2007-03-09 2009-12-02 Proteus Biomedical, Inc. In-body device having a multi-directional transmitter
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
ES2928197T3 (es) 2007-09-25 2022-11-16 Otsuka Pharma Co Ltd Dispositivo intracorpóreo con amplificación de señal de dipolo virtual
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
CN101926097B (zh) 2007-11-27 2016-10-05 普罗透斯数字保健公司 采用通信信道的穿体通信系统
DK3235491T3 (da) 2008-03-05 2021-02-08 Otsuka Pharma Co Ltd Spiselige hændelsesmarkeringsenheder og systemer med multimodus-kommunikation
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
CN104382598A (zh) 2008-08-13 2015-03-04 普罗透斯数字保健公司 一种产生识别器的方法
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
AU2009313879B2 (en) * 2008-11-13 2011-10-20 Proteus Digital Health, Inc. Ingestible therapy activator system and method
US8055334B2 (en) * 2008-12-11 2011-11-08 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
TWI503101B (zh) 2008-12-15 2015-10-11 波提亞斯數位康健公司 與身體有關的接收器及其方法
CA2750148C (en) 2009-01-06 2017-02-07 Proteus Biomedical, Inc. Pharmaceutical dosages delivery system
AU2010203625A1 (en) 2009-01-06 2011-07-21 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
BR122013009559A2 (pt) 2009-04-28 2019-08-06 Proteus Digital Health, Inc. Marcadores de evento de ingerível altamente confiável e métodos para usar os mesmos
EP2432458A4 (en) 2009-05-12 2014-02-12 Proteus Digital Health Inc ACCEPTABLE EVENT MARKER WITH SUGAR COMPONENT
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011022732A2 (en) 2009-08-21 2011-02-24 Proteus Biomedical, Inc. Apparatus and method for measuring biochemical parameters
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
KR101798128B1 (ko) 2010-02-01 2017-11-16 프로테우스 디지털 헬스, 인코포레이티드 데이터 수집 시스템
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011127252A2 (en) 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
DK2603232T3 (da) 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
EP2683291B1 (en) 2011-03-11 2019-07-31 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
BR112014001397A2 (pt) 2011-07-21 2017-02-21 Proteus Biomedical Inc dispositivo, sistema e método de comunicação móvel
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
EP2874886B1 (en) 2012-07-23 2023-12-20 Otsuka Pharmaceutical Co., Ltd. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
JP2016508529A (ja) 2013-01-29 2016-03-22 プロテウス デジタル ヘルス， インコーポレイテッド 高度に膨張可能なポリマーフィルムおよびこれを含む組成物
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
WO2015042411A1 (en) 2013-09-20 2015-03-26 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
JP2016537924A (ja) 2013-09-24 2016-12-01 プロテウス デジタル ヘルス， インコーポレイテッド 事前に正確に把握されていない周波数において受信された電磁信号に関する使用のための方法および装置
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
SG10202101937PA (en) 2016-07-22 2021-03-30 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers
WO2018081337A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
PE20231844A1 (es) * 2020-07-30 2023-11-21 Faes Farma Sa Sistema de liberacion de farmacos descongestivos y bilastina
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法
CN115647000B (zh) * 2022-10-26 2025-06-27 华能阜新风力发电有限责任公司 一种基于低温热解的风电叶片回收方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
AU3941493A (en) * 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
RU2005118101A (ru) 2006-01-20
MXPA05005812A (es) 2005-08-16
CN1726012A (zh) 2006-01-25
AU2003283688A1 (en) 2004-06-30
TW200425888A (en) 2004-12-01
ZA200503812B (en) 2006-07-26
WO2004052343A1 (en) 2004-06-24
CO5570656A2 (es) 2005-10-31
US20040121015A1 (en) 2004-06-24
EP1572163A1 (en) 2005-09-14
JP2006510655A (ja) 2006-03-30
NO20053068D0 (no) 2005-06-22
BR0317275A (pt) 2005-11-08
RU2308263C2 (ru) 2007-10-20
KR20050088311A (ko) 2005-09-05
PL377479A1 (pl) 2006-02-06
NZ539915A (en) 2007-09-28
NO20053068L (no) 2005-09-07
TWI257302B (en) 2006-07-01
AR042340A1 (es) 2005-06-15

Similar Documents

Publication Publication Date Title
US20040121015A1 (en) Controlled-Release of an active substance into a high fat environment
EP1242055B1 (en) Hydrogel-driven drug dosage form
Sungthongjeen et al. Development of pulsatile release tablets with swelling and rupturable layers
BG107538A (bg) Дозирана лекарствена форма с хидрогелен механизъм
US20240000701A1 (en) Self-regulating osmotic gastroretentive drug delivery systems
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
KR20080008352A (ko) 페노피브르산 및/또는 이의 염을 포함하는 경구 약제학적제형
WO2021014360A1 (en) Oral modified release dosage forms
JP5105684B2 (ja) 持続性医薬製剤
WO2007057762A2 (en) Osmotic bi-layer tablet
HK1083588A (en) Controlled-release of an active substance into a high fat environment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued